Evidence map›Paper›PMID 38467839›Full record

ArticleEMBO molecular medicine2024

Lipidomics reveals new lipid-based lung adenocarcinoma early diagnosis model.

Ting Sun, Junge Chen, Fan Yang, Gang Zhang, Jiahao Chen, Xun Wang, Jing Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. [Curcumin inhibits lipid metabolism in non-small cell lung cancer by downregulating the HIF-1α pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ting Sun *Key Laboratory for Biomechanics and Mechanobiology of Ministry of Education, Beijing Advanced Innovation Center for Biomedical Engineering, School of Biological Science and Medical Engineering, Beihang University, 100083, Beijing, China.
Junge Chen *Key Laboratory for Biomechanics and Mechanobiology of Ministry of Education, Beijing Advanced Innovation Center for Biomedical Engineering, School of Engineering Medicine, Beihang University, 100083, Beijing, China.ORCID 0000-0003-4687-884X
Fan YangDepartment of Thoracic Surgery, Peking University People's Hospital, 100044, Beijing, China.
Gang ZhangCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, 100190, Beijing, China.
Jiahao ChenKey Laboratory for Biomechanics and Mechanobiology of Ministry of Education, Beijing Advanced Innovation Center for Biomedical Engineering, School of Biological Science and Medical Engineering, Beihang University, 100083, Beijing, China.
Xun WangDepartment of Thoracic Surgery, Peking University People's Hospital, 100044, Beijing, China. wangxun04275@pkuph.edu.cn.
Jing ZhangKey Laboratory for Biomechanics and Mechanobiology of Ministry of Education, Beijing Advanced Innovation Center for Biomedical Engineering, School of Biological Science and Medical Engineering, Beihang University, 100083, Beijing, China. jz2716@buaa.edu.cn.
Beihang University · CNPeking University · CNNational Center for Nanoscience and Technology · CN

Funding

Beijing hospital Authority Clinical Medicine Development Special Funding Support ZLRK202333Beijing Natural Science Foundation L222097Clinical Medicine Plus X-Young Scholars Project of Peking Universities PKU2023LCXQ001Fundamental Research Funds for the General Universities J.Z.Guangdong Basic and Applied Basic Research Foundation 2021A1515110619National Natural Science Foundation of China 82202336Youth Thousand Scholar Program of China J.Z.
6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) continues to pose a significant mortality risk with a lack of dependable biomarkers for early noninvasive cancer detection. Here, we find that aberrant lipid metabolism is significantly enriched in lung cancer cells. Further, we identified four signature lipids highly associated with LUAD and developed a lipid signature-based scoring model (LSRscore). Evaluation of LSRscore in a discovery cohort reveals a robust predictive capability for LUAD (AUC: 0.972), a result further validated in an independent cohort (AUC: 0.92). We highlight one lipid signature biomarker, PE(18:0/18:1), consistently exhibiting altered levels both in cancer tissue and in plasma of LUAD patients, demonstrating significant predictive power for early-stage LUAD. Transcriptome analysis reveals an association between increased PE(18:0/18:1) levels and dysregulated glycerophospholipid metabolism, which consistently displays strong prognostic value across two LUAD cohorts. The combined utility of LSRscore and PE(18:0/18:1) holds promise for early-stage diagnosis and prognosis of LUAD.

Indexed as

Adenocarcinoma of LungLung NeoplasmsEarly Detection of CancerHumansLipidomicsLipidsLipidsCancer Early Diagnosis ModelLipid MetabolismLipidomicsLSRscoreLUAD

Identifiers

PMID38467839
PMCPMC11018865
OpenAlexW4392660562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.